文献速递浆细胞疾病

ICARIA-MM 高危细胞遗传学复发难治多发性骨髓瘤亚组分析

Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
PubMed 文献 · Br J Haematol · 2021-05-25

本文为 ICARIA-MM 三期试验的亚组分析,比较高危与标危细胞遗传学复发难治多发性骨髓瘤患者中 isatuximab 联合泊马度胺-地塞米松的获益。孤立 gain(1q21) 患者中亦见无进展生存期与缓解率改善。

要点

  • 高危细胞遗传学患者中 isatuximab 联合方案较对照改善 mPFS 与 ORR。
  • 高危患者接受 isatuximab 时 ≥3 级不良事件更多,但未增加导致停药的事件或治疗相关死亡。

核心结论

  • 在复发难治多发性骨髓瘤中,无论细胞遗传学风险如何,isatuximab 联合泊马度胺-地塞米松较泊马度胺-地塞米松均提供一致的获益。

研究设计与样本

  • ICARIA-MM 三期试验(NCT02990338)的亚组分析,307 例患者接受 isatuximab-泊马度胺-地塞米松(n=154)或泊马度胺-地塞米松(n=153)。
  • isatuximab 10 mg/kg 静脉给药,首个 28 天周期每周一次,此后每两周一次;泊马度胺-地塞米松按标准剂量给药。
  • 高危定义为存在 del(17p)、t(4;14) 或 t(14;16);另对 gain(1q21) 异常行回顾性亚组分析。

主要发现

  • isatuximab 未增加导致停药的事件或治疗相关死亡。

临床怎么用

  • 对伴高危细胞遗传学或 gain(1q21) 的复发难治多发性骨髓瘤患者,可考虑 isatuximab 联合泊马度胺-地塞米松方案。
  • 用药时需关注高危患者 ≥3 级不良事件发生率高,但不必因担心停药风险或治疗相关死亡而避免使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment benefit in multiple myeloma (MM) patients with high-risk cytogenetics remains suboptimal. The phase 3 ICARIA-MM trial (NCT02990338) showed that isatuximab plus pomalidomide-dexamethasone prolongs median progression-free survival (mPFS) in patients with relapsed/refractory MM (RRMM). This subgroup analysis of ICARIA-MM compared the benefit of isatuximab in high-risk [defined by the presence of del(17p), t(4;14) or t(14;16)] versus standard-risk patients. The efficacy of isatuximab in patients with gain(1q21) abnormality was also assessed in a retrospective subgroup analysis. In ICARIA-MM, 307 patients received isatuximab-pomalidomide-dexamethasone (n = 154) or pomalidomide-dexamethasone (n = 153). Isatuximab (10 mg/kg intravenously) was given weekly in the first 28-day cycle, and every other week thereafter. Standard pomalidomide-dexamethasone doses were given. Isatuximab-pomalidomide-dexamethasone improved mPFS (7·5 vs 3·7 months; HR, 0·66; 95% CI, 0·33-1·28) and overall response rate (ORR, 50·0% vs 16·7%) in high-risk patients. In patients with isolated gain(1q21), isatuximab addition improved mPFS (11·2 vs 4·6 months; HR, 0·50; 95% CI, 0·28-0·88) and ORR (53·6% vs 27·6%). More grade ≥3 adverse events occurred in high-risk patients receiving isatuximab (95·7%) versus the control group (67·6%); however, isatuximab did not increase events leading to discontinuation or treatment-related mortality. Isatuximab-pomalidomide-dexamethasone provides a consistent benefit over pomalidomide-dexamethasone treatment in RRMM patients regardless of cytogenetic risk.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Harrison SJ, Perrot A, Alegre A, et al. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol. 2021. PMID: 34036560. doi:10.1111/bjh.17499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。